NET LOSS PER SHARE (Tables)

3 Months Ended

Sep. 30, 2026

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of net loss per share for the periods presented:


	Three Months Ended September 30,
(in thousands, except per share amounts)		2026		2025
Numerator:
Net loss attributable to common shareholders, basic		$	(40,462)	$	(47,941)
Change in fair value of warrants(1)		—		—
Net loss attributable to common shareholders, diluted		(40,462)		(47,941)
Denominator:
Weighted-average common stock outstanding, basic		191,459		185,816
Stock options outstanding to purchase shares of common stock including unvested RSUs and from the ESPP(2)		—		—
Dilutive effect of warrants to purchase common stock		—		—
Weighted-average common stock outstanding, diluted		191,459		185,816

Net loss per share—basic:		$	(0.21)	$	(0.26)

Net loss per share—diluted:		$	(0.21)	$	(0.26)

(1) Includes the change in fair value of warrant liabilities to the extent the related warrants to purchase common stock are dilutive or the effect is dilutive.

(2) Excluded from the computation of net loss per share-diluted for the three months ended September 30, 2026, and September 30, 2025, because the effect would have been anti-dilutive.

Schedule of Antidilutive Securities Excluded from Computation of Income (Loss) Per Share

The weighted average potential shares of common stock that were excluded from the calculation of net loss per share-diluted for the periods presented because including them would have been anti-dilutive consisted of the following:


	Three Months Ended September 30,
(in thousands)		2026	2025



Stock options outstanding to purchase shares of common stock, unvested RSUs and shares from the ESPP		13,121	12,593

The weighted average potential shares of common stock that were excluded from the calculation of net loss per share-diluted because the performance or market conditions associated with these awards were not met are as follows for the periods presented:


	Three Months Ended September 30,
(in thousands)		2026	2025




Shares subject to outstanding PVUs		8,608	8,639

The weighted average potential shares of common stock that were excluded from the calculation of net loss per share-diluted because the exercise price of the warrants exceeded the average market price of the Company's common stock or the effect would have been anti-dilutive for the periods presented:


	Three Months Ended September 30,
(in thousands)		2026	2025




Warrants to purchase shares of common stock		18,744	24,942